FDA approves new drug for deadly kidney cancer

Mar 30, 2009

(AP) -- A drug from Novartis has won U.S. approval as a treatment for patients with kidney cancer that has returned after treatment with older drugs.

The approved the pill on Monday to treat renal cell cancer, the most common form of cancer.

The agency said patients tested with Novartis' Afinitor lived more than twice as long without as those who didn't receive the . The study by the Swiss drugmaker showed Afinitor delayed tumor growth nearly 5 months, compared with less than two months for patients not taking the drug.

Afinitor works by blocking a protein that helps divide and grow. The drug was approved for patients who have already taken Inc.'s Sutent and Bayer's Nexavar.

Kidney cancer is resistant to chemotherapy and radiation therapy, and the most effective remedy is usually to surgically remove the kidney. When the cancer is isolated to the kidney, a majority of patients will survive at least five years. If the cancer has spread to other parts of the body, the survival rate is much shorter.

About 13,000 patients died from the disease last year, according to the American Cancer Society.

Basel, Switzerland-based has submitted the drug for approval in the European Union, Japan and elsewhere.

Shares of Novartis fell 47 cents to close at $36.55 Monday.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: Mylan rebuffs Teva again; calls bid low, insincere

Related Stories

FDA OKs vitamin C trial for cancer

Jan 12, 2007

Federal approval of a clinical trial on intravenous vitamin C as a cancer treatment lends credence to alternative cancer care, U.S. researchers said.

Recommended for you

Mylan rebuffs Teva again; calls bid low, insincere

6 hours ago

Generic drug company Mylan rejected for the second time Monday a $40.1 billion takeover offer from Israeli pharmaceutical power Teva, just days after Mylan's own bid for rival Perrigo was rebuffed.

Rising antibiotic shortages raise concerns about patient care

Apr 23, 2015

Shortages of key antibiotics, including gold-standard therapies and drugs used to treat highly resistant infections, are on the rise, according to a new study of shortages from 2001 to 2013 published in Clinical Infectious Di ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.